Canopy Growth Corp (CGC)vsHaleon plc (HLN)
CGC
Canopy Growth Corp
$0.89
-0.53%
HEALTHCARE · Cap: $405.86M
HLN
Haleon plc
$10.28
+0.10%
HEALTHCARE · Cap: $43.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 3776% more annual revenue ($11.03B vs $284.60M). HLN leads profitability with a 15.1% profit margin vs -92.4%. HLN earns a higher WallStSmart Score of 63/100 (C+).
CGC
Avoid34
out of 100
Grade: F
HLN
Buy63
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -41.0% — below average capital efficiency
Negative free cash flow — burning cash
0.6% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CGC
The strongest argument for CGC centers on Price/Book.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : CGC
The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
CGC profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
CGC carries more volatility with a beta of 2.42 — expect wider price swings.
CGC is growing revenue faster at 9.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 34/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Canopy Growth Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?